Irreversible Electroporation Plus Anti-PD-1 Antibody versus Irreversible Electroporation Alone for Patients with Locally Advanced Pancreatic Cancer
Chaobin He,Shuxin Sun,Yu Zhang,Shengping Li
DOI: https://doi.org/10.2147/JIR.S331023
IF: 4.5
2021-09-21
Journal of Inflammation Research
Abstract:Chaobin He, 1, &ast Shuxin Sun, 2, &ast Yu Zhang, 3, &ast Shengping Li 1 1 Department of Pancreatobiliary Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China; 2 Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, People's Republic of China; 3 State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shengping Li Email Background: Irreversible electroporation (IRE) is shown to not only improve the prognosis of patients with locally advanced pancreatic cancer (LAPC) but also activate the immune system. Considering the immune-activating function of IRE, IRE may enhance the effect of immune checkpoint inhibitors in the treatment of LAPC. We aimed to compare the effect and safety of IRE combined with toripalimab versus IRE alone for LAPC. Methods: We retrospectively collected data from LAPC patients treated with IRE plus toripalimab (240mg, 7 days after IRE) or IRE alone at Sun Yat‐sen University Cancer Center. Overall and progression-free survival and treatment-related adverse events were evaluated and compared. Results: From August 2015 to June 2020, a total of 85 patients were collected and analyzed in this study: 70 in the IRE group and 15 in the IRE plus toripalimab group. The IRE plus toripalimab group showed longer OS [44.33 months (95% CI 17.39– 71.27) versus 23.37 months (95% CI 21.20– 25.54), P=0.010] and PFS [27.5 months (95% CI not reached) versus 10.6 months (95% CI 7.79– 13.42), P=0.036], compared with IRE group. There were no treatment-related deaths in all patients of this study. Although pancreatic fistula, biliary fistula, abscess, vomiting and gastroparesis were a little more common in IRE plus toripalimab group, no significant differences in the rates of all adverse events between these two groups were observed. Conclusion: IRE plus toripalimab had acceptable toxic effects and might improve survival in LAPC compared with IRE alone. Keywords: locally advanced pancreatic cancer, irreversible electroporation, toripalimab, efficacy, prognosis Pancreatic ductal adenocarcinoma (PDAC) is a lethal gastrointestinal disease with increasing morbidity, which also has a growing impact on cancer-specific mortality worldwide. 1 Nearly 40% of all PDAC cases are localized to the pancreas and characterized with the involvement of major vascular structures, leading to unresectable disease without metastases detected by radiological examinations, which are also known as locally advanced pancreatic cancer (LAPC). 2 Despite currently available therapies, the prognosis of LAPC remained unsatisfied with 3% as 5-year survival rate and 14.2 months as median survival. 3 The optimal treatment of LAPC was still controversial. Based on the development of chemotherapy, more choices for additional treatment, such as conversional surgical resection, were available. However, the rates of downstaging to resection were as low as 4–15%. 4 Moreover, more than 30% of deaths were due to the progression of local disease, 5 suggesting the importance of local control approaches. As an important local destructive method, local ablative therapy was used as a new treatment of LAPC. However, the thermal injury to the adjacent organs and vessels limited the use of most thermal ablative methods, including radiofrequency ablation and microwave ablation. 6,7 Instead of relying on thermal energy, IRE induces the apoptosis of tumor cells by destroying the cell membrane integrity with short and high-voltage current pulses. 8 The feature of free from the heat sink effect makes IRE more appropriate than radiofrequency ablation (RFA) in the treatment of LAPC. Additionally, the immune response caused by IRE may be stronger, because the advantage of preservation of vessels is helpful for the transmission of immune molecules or cells. Thus, apart from inducing apoptosis of tumor cells, IRE can also reconstruct the microenvironment within the tumor and induce the immune response. 9–11 Previous studies had shown that IRE could alleviate immune suppression and induce activation of T cells, indicating that IRE may potentiate the antitumor efficacy of immunotherapy in PDAC. 9,12 In recent years, game-changing advances have been achieved in the development of therapies of vario -Abstract Truncated-
immunology